CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis

Mir, Fozia; Lee, Donald; Ray, Hetal; Sadiq, Saud

doi:10.1212/nxi.0000000000000021

Cited by 22 publications

(19 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some isoprostanes have found clinical applications in obesity, ischemia-reperfusion injury, the central nervous system, cancer, and genetic disorders (Milne et al, 2015). CSF isoprostane levels have been beneficial in evaluating oxidative stress in multiple sclerosis in humans (Mir et al, 2014) whereas plasma or milk isoprostane levels were diagnostic for oxidative stress in lactating dairy cows (Vernunft et al, 2014).…”

Section: Types Of Biomarkersmentioning

confidence: 99%

Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values

Dhama

Latheef

Dadar

et al. 2019

Front. Mol. Biosci.

221

172

View full text Add to dashboard Cite

Various internal and external factors negatively affect the homeostatic equilibrium of organisms at the molecular to the whole-body level, inducing the so-called state of stress. Stress affects an organism's welfare status and induces energy-consuming mechanisms to combat the subsequent ill effects; thus, the individual may be immunocompromised, making them vulnerable to pathogens. The information presented here has been extensively reviewed, compiled, and analyzed from authenticated published resources available on Medline, PubMed, PubMed Central, Science Direct, and other scientific databases. Stress levels can be monitored by the quantitative and qualitative measurement of biomarkers. Potential markers of stress include thermal stress markers, such as heat shock proteins (HSPs), innate immune markers, such as Acute Phase Proteins (APPs), oxidative stress markers, and chemical secretions in the saliva and urine. In addition, stress biomarkers also play critical roles in the prognosis of stress-related diseases and disorders, and therapy guidance. Moreover, different components have been identified as potent mediators of cardiovascular, central nervous system, hepatic, and nephrological disorders, which can also be employed to evaluate these conditions precisely, but with stringent validation and specificity. Considerable scientific advances have been made in the detection, quantitation, and application of these biomarkers. The present review describes the current progress of identifying biomarkers, their prognostic, and therapeutic values.

show abstract

Section: Types Of Biomarkersmentioning

confidence: 99%

Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values

Dhama

Latheef

Dadar

et al. 2019

Front. Mol. Biosci.

221

172

View full text Add to dashboard Cite

show abstract

“…However, an increase in the CSF concentration of 8-iso-15( S )-PGF 2α was reported in the CSF of patients with MS with F 2 -IP determined by ELISA. 26 – 28 We attribute these apparent discrepancies to differences in the methods used to determine F 2 -IP. It is well known that results from ELISA are not directly comparable to those determined by mass spectrometry–based assays, 29 with the former being less specific and commonly yielding higher values for 8-iso-15( S )-PGF 2α than mass spectrometry–based assays.…”

Section: Discussionmentioning

confidence: 99%

Absence of systemic oxidative stress and increased CSF prostaglandin F _2α in progressive MS

Lam

Maghzal

Khademi

et al. 2016

Neurol Neuroimmunol Neuroinflamm

View full text Add to dashboard Cite

Objective:We aimed to investigate the role of oxidative stress in the progression of multiple sclerosis (MS).Methods:We determined by liquid chromatography–tandem mass spectrometry nonenzymatic (F2-isoprostanes) and enzymatic oxidation products of arachidonic acid (prostaglandin F2α [PGF2α]) in plasma and CSF of 45 controls (other neurologic disease [OND] with no signs of inflammation) and 62 patients with MS. Oxidation products were correlated with disease severity and validated biomarkers of inflammation (chemokine ligand 13; matrix metalloproteinase-9; osteopontin) and axonal damage (neurofilament light protein).Results:Compared with OND controls, plasma concentrations of F2-isoprostanes and PGF2α were significantly lower in patients with progressive disease, and decreased with increasing disability score (Expanded Disability Status Scale). In contrast, CSF concentrations of PGF2α, but not F2-isoprostanes, were significantly higher in patients with progressive disease than OND controls (p < 0.01). The content of PGF2α in CSF increased with disease severity (p = 0.044) and patient age (p = 0.022), although this increase could not be explained by age. CSF PGF2α decreased with natalizumab and methylprednisolone treatment and was unaffected by the use of nonsteroidal anti-inflammatory drug in secondary progressive MS. CSF PGF2α did not associate with validated CSF markers of inflammation and axonal damage that themselves did not associate with the Expanded Disability Status Scale.Conclusions:Our data suggest that MS progression is associated with low systemic oxidative activity. This may contribute to immune dysregulation with CNS inflammation accompanied by increased local cyclooxygenase-dependent lipid oxidation.

show abstract

“…CSF studies have confirmed isoprostane levels are increased in MS compared to controls [93][94][95][96].…”

Section: Csfmentioning

confidence: 93%

Oxidative Stress-Related Biomarkers in Multiple Sclerosis: A Review

et al. 2016

View full text Add to dashboard Cite

General rightsThis document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms AbstractObjective: To provide an up to date review of oxidative stress biomarkers in multiple sclerosis and thus identify candidate molecules with greatest promise as biomarkers of diagnosis, disease activity or prognosis.Method: A semi-systematic literature search using PubMed and other databases.Results: Nitric oxide metabolites, superoxide dismutase, catalase, glutathione reductase, inducible nitric oxide synthase, protein carbonyl, 3-nitrotyrosine, isoprostanes, malondialdehyde and products of DNA oxidation have been identified across multiple studies as having promise as diagnostic, therapeutic or prognostic markers in MS.Conclusion: Heterogeneity of study design, particularly patient selection, limits comparability across studies. Further cohort studies are needed, and we would recommend promising markers be incorporated into future clinical trials to prospectively validate their potential.

show abstract

CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis

Cited by 22 publications

References 33 publications

Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values

Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values

Absence of systemic oxidative stress and increased CSF prostaglandin F _2α in progressive MS

Oxidative Stress-Related Biomarkers in Multiple Sclerosis: A Review

Contact Info

Product

Resources

About

CSF isoprostane levels are a biomarker of oxidative stress in multiple sclerosis

Cited by 22 publications

References 33 publications

Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values

Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values

Absence of systemic oxidative stress and increased CSF prostaglandin F 2α in progressive MS

Oxidative Stress-Related Biomarkers in Multiple Sclerosis: A Review

Contact Info

Product

Resources

About

Absence of systemic oxidative stress and increased CSF prostaglandin F _2α in progressive MS